Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7481 pages
Showing 6551 - 6600Do Survival Gains Match More Intense Treatment in Younger Patients With Colon Cancer?
In a study reported in JAMA Surgery, Kneuertz et al found that the more frequent stage-specific use of adjuvant chemotherapy in younger patients with colon cancer did not appear to produce commensurate benefit in survival compared with outcomes in older patients. Study Details The study was a...
Statin Use Is Associated With Reduced Risk of Primary Liver Cancer in Low-Prevalence Setting
In a study reported in the Journal of the National Cancer Institute, McGlynn et al found that statin use was associated with a reduced risk of primary liver cancer in a setting of low liver cancer prevalence. Other studies have shown a preventive benefit of statin therapy in regions of the world...
Ibrutinib Is Highly Active in Previously Treated Waldenström’s Macroglobulinemia
In a study reported in The New England Journal of Medicine, Treon et al found that ibrutinib (Imbruvica) was highly active and produced durable responses in patients with previously treated Waldenström’s macroglobulinemia. Response rates were highest in patients with MYD88 mutation and...
Similar Outcomes With Laparoscopic vs Open Resection in Rectal Cancer
In the COLOR II study reported in The New England Journal of Medicine, Bonjer et al found similar rates of locoregional recurrence and disease-free and overall survival with laparoscopic vs open resection of rectal cancer. Study Details In the trial, 1,044 patients from 30 sites in 8 countries in ...
Less Than 95% Adherence to Mercaptopurine Maintenance Associated With Nearly Threefold Increased Risk of Relapse in Pediatric ALL
In a Children’s Oncology Group study (COG-AALL03N1) reported in JAMA Oncology, Bhatia et al found that < 95% adherence to mercaptopurine treatment was associated with a nearly threefold increase in the risk of relapse in children with acute lymphoblastic leukemia (ALL). Among adherent...
Circulating Tumor Cell Count and LDH Level as Patient-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer
In an analysis reported in the Journal of Clinical Oncology, Scher et al found that circulating tumor cell count and LDH level served as an individual-level surrogate for survival among patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate (Zytiga) plus...
No Survival Benefit of Vorinostat in Progressive Advanced Malignant Pleural Mesothelioma
In the phase III VANTAGE-014 study reported in The Lancet Oncology, Krug et al found that treatment with the histone deacetylase inhibitor vorinostat (Zolinza) did not improve overall survival vs placebo in patients with malignant pleural mesothelioma who had progressed on previous chemotherapy....
Regional-Level Correlation of Inappropriate Prostate Imaging and Inappropriate Breast Imaging
In a study reported in JAMA Oncology, Makarov et al found that hospital referral regions marked by higher rates of inappropriate imaging in patients with low-risk breast cancer also had high rates of inappropriate prostate imaging in patients with low-risk prostate cancer. Inappropriate imaging...
Platinum Monotherapy Particularly Active in BRCA1/2-Mutant Metastatic Triple-Negative Breast Cancer
In the phase II TBCRC009 trial reported in the Journal of Clinical Oncology, Isakoff et al found that platinum monotherapy was active in treatment of metastatic triple-negative breast cancer, particularly in cases with BRCA1/2 mutation, and that an assay of genomic instability characteristic of...
Neoadjuvant Iniparib Plus Gemcitabine-Carboplatin Is Active in Early Triple-Negative and BRCA1/2-Mutant Breast Cancer
In the phase II PrECOG 0105 study reported in the Journal of Clinical Oncology, Telli et al found that neoadjuvant iniparib plus gemcitabine-carboplatin was active in early-stage triple-negative and BRCA1/2-mutant breast cancer. Higher score on a homologous recombination deficiency–loss of...
Complete Regression of Metastatic Cervical Cancer Is Observed After Treatment With HPV-Targeted Tumor-Infiltrating T Cells
As reported in the Journal of Clinical Oncology, Stevanovíc et al observed complete regression of metastatic cervical tumors in two patients following a single infusion of human papillomavirus (HPV)-targeted tumor-infiltrating T cells. In the protocol, nine patients with metastatic cervical ...
Durable Responses With Nivolumab in Previously Treated Advanced Renal Cell Carcinoma
In a phase I cohort-expansion study reported in the Journal of Clinical Oncology, McDermott et al found that nivolumab (Opdivo) produced durable responses in patients with previously treated advanced renal cell carcinoma. Responses continued after nivolumab discontinuation in some patients. Study...
NPM1-Positive/FLT3-ITD–Negative Genotype Not Associated With Significantly Better Prognosis in Older AML Patients
In a study reported in the Journal of Clinical Oncology, Ostronoff et al found that the presence of the NPM1-positive/FLT3-internal tandem duplication (ITD)–negative genotype—which is recognized as a marker of better prognosis in younger patients with acute myeloid leukemia—was...
Worse Outcomes With Lapatinib vs Trastuzumab Plus Taxane in Advanced HER2-Positive Breast Cancer
In the phase III National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) MA.31 trial, first-line treatment with lapatinib (Tykerb) vs trastuzumab (Herceptin) combined with a taxane was associated with poorer progression-free survival and greater toxicity in patients with advanced...
Weak Relationship Between Surgical Oncologic Perioperative Morbidity and Publicly Reported Hospital Quality and Satisfaction Measures
In a study reported in the Journal of the National Cancer Institute, Wright et al found a weak relationship between measures of patient satisfaction and quality and surgical oncologic perioperative outcomes at the hospital level. Study Details In the study, the Nationwide Inpatient Sample...
Adjuvant Ipilimumab Increases Recurrence-Free Survival vs Placebo After Complete Resection of High-Risk Stage III Melanoma
In the phase III EORTC 18071 trial reported in The Lancet Oncology, Eggermont et al found that adjuvant ipilimumab (Yervoy) significantly improved recurrence-free survival vs placebo in patients with completely resected stage III melanoma at high risk of disease recurrence. Ipilimumab was...
Analysis Indicates Poorer Progression-Free and Overall Survival With Lower Baseline Vitamin D Levels in Follicular Lymphoma Patients
In an analysis reported in the Journal of Clinical Oncology, Kelly et al found that low baseline serum vitamin D levels are associated with poorer progression-free and overall survival in patients with previously untreated follicular lymphoma. Study Details The study involved analysis of data...
Persistence of HER2-Specific CAR T Cells in HER2‑Positive Sarcoma
In a phase I/II study reported in Journal of Clinical Oncology, Ahmed et al found that infusion of T cells expressing HER2-specific chimeric antigen receptor (CAR) with a CD28.ζ signaling domain (HER2-CAR T cells) could produce persistent CAR T cell levels for ≥ 6 weeks in patients with...
Improved Quality Metrics for Robotic Pancreaticoduodenectomy With Increased Performance
In a retrospective single-institution study reported in JAMA Surgery, Boone et al found significant improvements in blood loss, incidence of conversion to open surgery, pancreatic fistula incidence, and operative time with increased number of patients treated with robotic pancreaticoduodenectomy....
Five-Year Analysis Indicates Potential for Long‑Term Survival With Ipilimumab Plus Dacarbazine in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Maio et al found a 5-year survival rate of 18% among treatment-naive patients receiving ipilimumab (Yervoy) plus dacarbazine in a phase III trial. The findings support other data indicating long-term survival in some patients receiving...
Improved Progression-Free Survival With Brentuximab Vedotin Consolidation After Transplantation in Hodgkin Lymphoma
In the phase III AETHERA trial reported in The Lancet, Moskowitz et al found that brentuximab vedotin (Adcetris) consolidation therapy after autologous stem cell transplantation prolonged progression-free survival by 18 months vs placebo in patients with Hodgkin lymphoma at risk for relapse or...
Substantial Pathologist Diagnostic Disagreement for Breast Biopsy Specimens
In a study reported in JAMA, Elmore et al found a substantial rate of disagreement between pathologist diagnosis based on single breast biopsy slides and the consensus-derived diagnosis of a panel of pathologists. Disagreement rates were highest for ductal carcinoma in situ (DCIS) and atypical...
Low Use of Decision Aids for Localized Prostate Cancer by Radiation Oncologists and Urologists
In a survey study reported in JAMA Internal Medicine, Wang et al found that a minority of responding radiation oncologists and urologists used decision aids for localized prostate cancer in clinical practice. Study Details In the study, a survey regarding use of and attitudes toward decision aids ...
Nivolumab Increases Response Rate vs Chemotherapy in Advanced Melanoma With Progression After Anti–CTLA-4 Treatment
In the phase III CheckMate 037 trial reported in The Lancet Oncology, Weber et al found that treatment with the PD-1 inhibitor nivolumab (Opdivo) resulted in a significantly greater response rate vs chemotherapy as second- or later-line treatment in patients with advanced melanoma progressing after ...
Translocation t(11;14) Associated With Poorer Outcome in Bortezomib-Treated Newly Diagnosed Amyloid Light-Chain Amyloidosis
In a single-institution study reported in the Journal of Clinical Oncology, Bochtler et al found that presence of the t(11;14) translocation on interphase fluorescence in situ hybridization (iFISH) was associated with poorer hematologic event-free and overall survival in patients receiving...
No Differences in Patient-Reported Outcomes or Resource Use With Early vs Delayed Initiation of Palliative Care Intervention
In the ENABLE III study reported in the Journal of Clinical Oncology, Bakitas et al found that early vs delayed initiation of a palliative care intervention did not result in improved patient-reported outcomes or resource use. Early initiation was associated with better 1-year survival. Study...
Reduced Family Caregiver Depression With Early vs Delayed Palliative Care Intervention for Caregivers
In the ENABLE III study reported in the Journal of Clinical Oncology, Dionne-Odom et al found that early vs delayed use of a palliative care intervention for family caregivers of patients with advanced cancer reduced caregiver depression scores and caregiver stress burden. No differences in...
Single Nucleotide Polymorphisms Associated With Colorectal Cancer Preventive Effect of Aspirin or NSAIDs in Persons of European Descent
In a study reported in JAMA, Nan et al found that two single nucleotide polymorphisms (SNPs) were associated with a reduced risk of colorectal cancer with regular aspirin or nonsteroidal anti-inflammatory drug (NSAID) use by persons of European descent. Study Details The case-control study...
Gonadotropin-Releasing Hormone Agonist Treatment and Orchiectomy Linked to Increased Risk of Cardiovascular Disease in Men With Prostate Cancer
In a study of Swedish men with prostate cancer reported in the Journal of Clinical Oncology, O’Farrell et al found that use of gonadotropin-releasing hormone (GnRH) agonists and orchiectomy were associated with a significantly increased risk of incident cardiovascular disease. In patients...
Intraperitoneal Chemotherapy Associated With Long-Term Survival Advantage Over Intravenous Chemotherapy in Advanced Ovarian Cancer
In an analysis of Gynecologic Oncology Group (GOG) studies reported in the Journal of Clinical Oncology, Tewari et al found that intraperitoneal chemotherapy was associated with a survival advantage compared with intravenous chemotherapy in women with advanced ovarian cancer. Study Details The...
Italian Trial Shows Benefit of Dose-Dense Adjuvant Therapy With Sequential Epirubicin-Cyclophosphamide-Paclitaxel in Early Node-Positive Breast Cancer
In an Italian 2×2 phase III trial reported in The Lancet, Del Mastro et al found that dose-dense adjuvant therapy with sequential epirubicin, cyclophosphamide, and paclitaxel (EC-P) with or without fluorouracil (5-FU) increased disease-free survival vs standard-interval therapy in early-stage ...
Insufficient Awareness of Breast Density and Its Impact on Breast Cancer Detection and Risk
In a study reported in the Journal of Clinical Oncology, Rhodes et al found that only about half of screening-age women had awareness of breast density and adequate knowledge of its impact on breast cancer detection and risk. Breast density is an important factor contributing to false-negative...
Improved Outcome and Greater Use of Adjuvant Chemotherapy With Laparoscopic vs Open Colectomy in Nonmetastatic Colon Cancer
In a National Cancer Data Base analysis reported in the Journal of the National Cancer Institute, Zheng et al found that laparoscopic colectomy was associated with lower 30-day mortality, shorter length of stay, and, in patients with stage III disease, greater use of adjuvant chemotherapy vs open...
No Survival Benefit of IGF-1R/Insulin Receptor Inhibitor Linsitinib in Advanced Adrenocortical Carcinoma
In a phase III trial reported in The Lancet Oncology, Fassnacht et al found that linsitinib, an insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor inhibitor, did not improve overall survival vs placebo in patients with previously treated locally advanced or metastatic...
Low Nadir Testosterone in First Year of Hormone Therapy Linked to Improved Cause-Specific Survival and Delay of Hormone Resistance in Prostate Cancer
In an analysis from the PR-7 trial reported in the Journal of Clinical Oncology, Klotz et al found that in men with prostate cancer with biochemical failure after radiotherapy with or without surgery, a nadir serum testosterone level ≤ 0.7 nmol/L during the first year of continuous...
Elevated C-Reactive Protein Associated With Poorer Outcome in Melanoma
In a study reported in the Journal of Clinical Oncology, Fang et al found that an elevated C-reactive protein level was associated with poorer overall and melanoma-specific survival in patients with melanoma and that sequential increases in C-reactive protein were associated with an increased risk...
No Improvement in Complete Remission Rate With Cytarabine Plus Amonafide L-Malate vs Daunorubicin in Secondary AML
In a phase III trial reported in the Journal of Clinical Oncology, Stone et al found that the combination of cytarabine and amonafide L-malate, a DNA intercalator and non–ATP-dependent topoisomerase II inhibitor, did not improve complete remission rate compared with cytarabine plus...
Marked Increase in Fracture Risk in Patients Receiving Hematopoietic Stem Cell Transplantation
In a single-institution retrospective study reported in the Journal of Clinical Oncology, Pundole et al found that patients undergoing hematopoietic stem cell transplantation are at increased risk of bone fracture later in life, with risk being particularly elevated in women and men aged 45 to 64...
Decline in Proportion of Lung Cancer Patients Meeting Screening Criteria
In a study reported in a research letter in JAMA, Wang et al found that the proportion of patients with lung cancer who would have met U.S. Preventive Services Task Force (USPSTF) criteria for low-dose computed tomography (CT) lung screening decreased significantly between the periods of 1984 to...
PET-Adapted Sequential Salvage Therapy With Brentuximab and Augmented ICE Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma
In a phase II study reported in The Lancet Oncology, Moskowitz et al found that a salvage strategy involving brentuximab vedotin (Adcetris) treatment followed by 18F-fluorodeoxyglucose positron-emission tomography (PET) and augmented ifosfamide, carboplatin, and etoposide (ICE) in PET-positive...
No Difference in Event-Free Survival With Stem Cell Transplantation Using Matched Unrelated vs Sibling Donor Grafts in Children With ALL
In a European trial (Berlin-Frankfurt-Muenster study group trial ALL-SCT-BFM 2003) reported in the Journal of Clinical Oncology, Peters et al found no difference in event-free survival with stem cell transplantation using matched unrelated vs sibling donors in pediatric patients with high-risk...
European Retrospective Study Shows Activity of Crizotinib in Advanced Lung Adenocarcinoma With ROS1 Rearrangement
In a retrospective study in the European EUROS1 cohort reported in the Journal of Clinical Oncology, Mazières found that crizotinib (Xalkori) treatment was associated with an 80% response rate in patients with stage IV lung adenocarcinoma with ROS1 rearrangement. Study Details The study...
Addition of Lenalidomide to Docetaxel-Prednisone Worsens Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
In the phase III MAINSAIL trial reported in The Lancet Oncology, Petrylak et al found that the addition of lenalidomide (Revlimid) to docetaxel-prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer was associated with significantly worse overall survival. The...
Vegetarian Dietary Pattern, Particularly Pescovegetarian Pattern, Is Associated With Reduced Risk of Colorectal Cancer
In a study reported by Orlich et al in JAMA Internal Medicine, a vegetarian dietary pattern was associated with a reduced risk of colorectal cancer, with risk reduction appearing to be greatest in pescovegetarians. Study Details The study involved data from 77,659 participants in the Adventist...
Comprehensive Genomic Profiling Shows Distribution of Targetable Alterations in Carcinomas of Unknown Primary Site
In a study reported in JAMA Oncology, Ross et al found potentially targetable genomic alterations in most carcinomas of unknown primary site using comprehensive genomic profiling. Adenocarcinomas of unknown primary site frequently harbored receptor tyrosine kinase/Ras/MAPK pathway alterations....
Nivolumab Shows Activity in Advanced, Refractory Squamous NSCLC
In the phase II CheckMate 063 study reported in The Lancet Oncology, Rizvi et al found that the PD-1 inhibitor nivolumab (Opdivo) produced durable responses in some patients with advanced, refractory squamous non–small cell lung cancer (NSCLC) who had received at least two prior treatments....
Addition of Aprepitant to Ondansetron Effective in Preventing Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
In a phase III trial reported in The Lancet Oncology, Kang et al found that adding aprepitant to ondansetron with or without dexamethasone was effective in preventing chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately or highly emetogenic chemotherapy. Study...
Findings in Pooled Analysis of Long-Term Survival With Ipilimumab in Advanced Melanoma
In a pooled analysis reported in the Journal of Clinical Oncology, Schadendorf et al found 3-year overall survival rates of 26% and 20% in treatment-naive and previously treated patients receiving ipilimumab (Yervoy)-based treatment for unresectable or metastatic melanoma. A survival curve plateau...
Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma Defined by BRAF Mutation and CDKN2A Deletion
In a study reported in the Journal of Clinical Oncology, Mistry et al found that presence of BRAF V600E mutation and CDKN2A deletion defined a clinically distinct subtype of pediatric secondary high-grade glioma. BRAF V600E mutation was associated with a prolonged time to transformation. Study...
Goserelin Provides Ovarian Protection During Adjuvant Chemotherapy for Breast Cancer
In the phase III POEMS/S0230 trial reported in The New England Journal of Medicine, Moore et al found that treatment with the gonadotropin-releasing hormone agonist goserelin (Zoladex) reduced risk of ovarian failure during chemotherapy for breast cancer in premenopausal women. Study Details In...
